1155: Treatment and degree of control of asthma in primary care. ASMADUAL Study

V. Lopez Marina1, P. Rubinstein Aguñín2, P. Gonzales Flores3, A. Pedro Pijoan4, J. Seuba5, N. Perallons Solans6, M. Mourelo Cejeiro7, A. Brau Tarrida8, M. De la Poza9, ASMADUAL GROUP2
1 Instituto Catalán de la Salud, ABS Piera, Barcelona, Spain; 2 Pneumologia, Capio Hospital General de Cataluña, Barcelona, Spain; 3 Instituto Catalán de la Salud, ABS La Farigola, Barcelona, Spain; 4 Instituto Catalán de la Salud, ABS Gaudí Sagrada Familia, Barcelona, Spain; 5 Medicina, Centre Mèdic Casteldefells, Barcelona, Spain; 6 Instituto Catalán de la Salud, ABS Polinya, Barcelona, Spain; 7 Instituto Catalán de la Salud, ABS Gòtic, Barcelona, Spain; 8 Instituto catalán de la Salud, ABS La Mina, Barcelona, Spain; 9 Instituto Catalán de la Salud, ABS Carles Ribas, Barcelona, Spain
Objective: To describe the pharmacological treatment, adverse effects and degree of control of asthmatics.
Methodology: Descriptive, cross-sectional study, multicentre across Catalonia; 55 physicians (family, Allergists, pulmonologists and internists) from primary care Centres that became a self-administered survey their asthmatic in February to April, 2012. Variables: sex; age; smoking; treatments; adverse effects (AE); degree by the Asthma Control Test and control (ACT≤19 insufficient control, and > 19 good control (GC)). Statistics: mean (X), standard deviation (SD), percentages, T-Student independent and test exactly of Fisher.
Results: Asthmatic 578, 70% women and age (X±DE) 47, 3±17, 5 years. 12.8% smoke. Treatments: 89% takes any treatment; salbutamol 48%, budesonide/formoterol 28%, 18% budesonide, fluticasone/salmeterol 17%, 13% montelukast, etc; pAdverse effects: 14.1% had AE; tachycardia 35.5%, neuromuscular 47%, oropharyngeal 21%, p19 (pConclusions: Asthmatics are middle-aged and it hurts them tobacco.
90% takes drugs (inhalers), 14% showing adverse effects.
A 68.5% regard good control perception, but according to the ACT only 53.7% presents sufficient control, with involvement by more than 60% of patients with insufficient control.

Disclosure: No conflict of interest declared